ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020
Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO).
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The Impact of Oncological Treatments on Return to Work, Work Ability, and Sickness Absence in Breast Cancer Survivors: A Systematic Review.Journal of occupational rehabilitation · 2026Pooled it
- Risk factors for return to work in workers who experienced cancer: a systematic review with meta-analysis.Oncology reviews · 2026Pooled it
- Prognostic factors for return to work in breast cancer survivors.The Cochrane database of systematic reviews · 2025Pooled it
- Investigating how cancer-related symptoms influence work outcomes among cancer survivors: a systematic review.Journal of cancer survivorship : research and practice · 2022Pooled it
- Psychological problems among cancer patients in relation to healthcare and societal costs: A systematic review.Psycho-oncology · 2021Pooled it
- Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).JCO oncology practice · 2025Trial
- Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Targeted self-management limits fatigue for women undergoing radiotherapy for early breast cancer: results from the ACTIVE randomised feasibility trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Trial
- Investigating the effectiveness of adjuvant therapy for patients with hormone receptor-positive ductal carcinoma in situ.PloS one · 2022Trial
- Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART).BMJ (Clinical research ed.) · 2021Trial
- Realist Collaborative Evaluation of a Work Disability Prevention Program for Breast Cancer Survivors: Protocol for a RECOVA-FASTRACS Realist Evaluation.JMIR research protocols · 2026Article
- Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study.British journal of cancer · 2026Article
- The long road after breast cancer: survivorship issues and long-term treatment effects in young women.Frontiers in oncology · 2026Review
- Work Reintegration After Chemotherapy in Patients With Early-Stage Breast Cancer: The RESTART Cross-Sectional Survey.Cureus · 2025Article
- Association between return-to-work trajectories and depressive symptoms in long-term breast cancer survivors: results from the French CONSTANCES cohort.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Review
- Validation of the Brazilian Version of the World Health Organization Disability Assessment Schedule (WHODAS 2.0) for Women After Breast Cancer Surgery.Physiotherapy research international : the journal for researchers and clinicians in physical therapy · 2025Article
- Return to Work After Breast Cancer Diagnosis and Treatment in Uruguay: Challenges and Determining Factors.Cureus · 2025Article
- Using machine learning to identify speech markers of subjective cognitive impairment in breast cancer survivors.Journal of cancer survivorship : research and practice · 2025Article
- Development of digital self-management support for breast cancer survivors: ensuring evidence-based approaches and patient engagement from concept to implementation.ESMO real world data and digital oncology · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdverse effects of breast cancer treatment can negatively affect survivors' work ability. Previous reports lacked detailed clinical data or health-related patient-reported outcomes (PROs) and did not prospectively assess the combined impact of treatment and related sequelae on employment.
methodsWe used a French prospective clinical cohort of patients with stage I-III breast cancer including 1,874 women who were working and ≥ 5 years younger than legal retirement age (≤ 57 years) at breast cancer diagnosis. Our outcome was nonreturn to work (non-RTW) 2 years after diagnosis. Independent variables included treatment characteristics as well as toxicities (Common Toxicity Criteria Adverse Events [CTCAE] v4) and PROs (European Organization for Research and Treatment of Cancer [EORTC] Quality of life Questionnaires, Breast cancer module [QLQ-BR23] and Fatigue module [QLQ-FA12], Hospital Anxiety and Depression Scale) collected 1 year after diagnosis. Logistic regression models assessed correlates of non-RTW, adjusting for age, stage, comorbidities, and socioeconomic covariates.
resultsTwo years after diagnosis, 21% of patients had not returned to work. Odds of non-RTW were significantly increased among patients treated with combinations of chemotherapy and trastuzumab (odds ratio [OR]
conclusionReceipt of systemic therapy combinations including trastuzumab was associated with increased odds of non-RTW. Likelihood of unemployment was also higher among patients who reported severe physical and psychological symptoms. This comprehensive study identifies potentially vulnerable patients and warrants supportive interventional strategies to facilitate their RTW.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.